[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endothelial-cell-loss-corneal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endothelial-cell-loss-corneal":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100484374","phase-1-safety-and-tolerability-of-eo2002-100484374",false,"NCT05587205","Safety and Tolerability of EO2002","Phase 1, Randomized, Masked, Sham-Controlled Study to Assess the Safety and Tolerability of EO2002 in Subjects Undergoing Cataract Surgery","Key Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Subject has uncomplicated history of cataract that has progressed to a level requiring standard cataract extraction with intraocular lens implant surgery.\n3. Decreased endothelial cell count\n\nExclusion Criteria:\n\nAll ocular criteria apply to study eye unless otherwise noted.\n\n1. Other corneal disease\n2. Macular disease that in the investigator and\u002For sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.\n3. Descemet membrane detachment.\n4. History of uveitis or other ocular inflammatory disease.\n5. History of incisional glaucoma surgery\n6. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.\n7. History of ocular neoplasm.\n8. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20\u002F200).\n9. Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.\n10. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.\n11. Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.",[26,27],"Cataract","Endothelial Cell Loss, Corneal","RECRUITING","2025-12-02",{"date":31,"type":32},"2025-12-08","ACTUAL",{"date":34,"type":32},"2022-08-30",{"date":36,"type":20},"2026-10-06",{"name":38,"class":39},"Asociación para Evitar la Ceguera en México","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100576182","effect-of-vitamin-c-supplementation-in-corneal-endothelial-damage-in-phacoemulsification-of-patients-with-hard-cataracts-100576182","NCT06781970","Effect of Vitamin C Supplementation in Corneal Endothelial Damage in Phacoemulsification of Patients with Hard Cataracts","The Effects of Vitamin C Supplementation on Corneal Endothelial Damage in Hard Cataract Phacoemulsification: an Oxidative Stress Study on Aqueous Humour and Corneal Endothelial Cell Characteristics.","Inclusion Criteria:\n\n* Males and females aged 60 years or older\n* Patients with immature senile cataracts in one or both eyes, with LOC (lens opacities classification) III nuclear opacity grade 4-6 and nuclear color grade 4-6 criteria\n* Patients willing to undergo phacoemulsification cataract surgery and consume the study medication as allocated, as well as participate in follow-up assessments for 7 weeks\n* Patients with no history of previous intraocular surgery\n* Patients with no history of allergy to vitamin C\n* Patients not routinely consuming other vitamins\n* Patients who agree to and sign the informed consent for the study\n\nExclusion Criteria:\n\n\\-","60 Years",{"count":50,"type":20},120,[52],"NA","The goal of this clinical trial is to analyze the protective effects of oral ascorbic acid on the corneal endothelial layer undergoing oxidative stress due to phacoemulsification in patients with hard cataracts. The main questions it aims to answer are:\n\n1. Will oral vitamin C administration provide better protection to the corneal endothelium in hard cataract phacoemulsification by comparing preoperative and postoperative administration, preoperative only, and no administration?\n2. How does oxidative stress (MDA levels) in the aqueous humour increase after oral vitamin C administration compared to no administration?\n3. Will there any changes in MDA levels in the aqueous humour and blood after oral vitamin C administration compared to no administration?\n4. Does MDA levels in the aqueous humour correlate with MDA levels in the blood?\n\nResearchers will compare vitamin C to a placebo to see if vitamin C as an antioxidant works in preventing corneal endothelial damage due to phacoemulsification.\n\nParticipants will:\n\n* Take 500 mg of oral vitamin C or placebo three times a day for seven days prior to phacoemulsification\n* Undergo phacoemulsification\n* Take vitamin C or placebo three times a day for 28 days after phacoemulsification\n* Visit the ophthalmology clinic 1, 7, 28, and 42 days post-operative for checkups\n* Keep a logbook to record the drug they take and to write symptoms of possible side effect of the drug",[27,55],"Cataract and Intraocular Lens (IOL) Surgery",[26,57,58,59,60,61,62],"Corneal Endothelial Damage","Phacoemulsification","Total Antioxidant Capacity","Ascorbic Acid","Vitamin C Supplementation","malondialdehyde","2025-01-13",{"date":65,"type":32},"2025-01-17",{"date":67,"type":32},"2024-12-07",{"date":69,"type":20},"2025-06",{"name":71,"class":39},"Indonesia University"]